To determine whether or not the transcription of BCR/ABL gene played a key role in the pathogenesis of CML, we treated the NOD/DCID mice with actinomycin D (7.0 μg/kg), an inhibitor of de novo mRNA synthesis. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.